Info
Advanced Targeting of the Lymphatic System / / edited by Namdev Dhas, Jayvadan K. Patel, Yashwant V. Pathak
| Advanced Targeting of the Lymphatic System / / edited by Namdev Dhas, Jayvadan K. Patel, Yashwant V. Pathak |
| Edizione | [1st ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (517 pages) |
| Disciplina | 612.42 |
| Soggetto topico |
Lymphatics
Drug delivery systems Toxicology Lymphatic System Drug Delivery |
| ISBN | 3-031-64828-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Lymphatic System: History, Anatomy, Physiology, challenges and opportunities -- Advancements in Brain Lymphatic system and its Involvement in Neurological Diseases -- Lymphatic system in the Eye: Advancements, challenges and opportunities -- Lymphatic system in Pancreas -- Lymphatic system in cardiovascular disease -- Lymphatic system in Gastro-intestinal tract -- Lymphatic System in Liver -- Lymphatic system in Kidney and related diseases -- Lymphatic system in lungs -- Lymphatic system and Dysfunctions in the context of male and female -- Physicochemical properties of carriers for targeting lymphatic system -- Lipid-based carriers for targeting lymphatic system -- Polymer-based carriers for targeting lymphatic system -- Metal-based carriers for targeting lymphatic system -- Route of administration for carriers for lymphatic delivery -- Nanoparticles for imaging of lymphatic system: Challenges and future perspective -- Nanoparticles in targeting lymphatic system for cancer treatment -- Transdermal application of nanoparticles for targeting lymphatic system -- Lymphatic Tissue Engineering and Regeneration -- Lymphatic system and immune cell-based response -- Biomaterials for Neurotrauma Intervention -- Challenges and Limitations of the Lymphatic Drug Delivery Systems. |
| Record Nr. | UNINA-9910887888203321 |
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibody-mediated drug delivery systems [[electronic resource] ] : concepts, technology, and applications / / edited by Yashwant Pathak, Simon Benita
| Antibody-mediated drug delivery systems [[electronic resource] ] : concepts, technology, and applications / / edited by Yashwant Pathak, Simon Benita |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (542 p.) |
| Disciplina | 615.37 |
| Altri autori (Persone) |
PathakYashwant
BenitaSimon <1947-> |
| Soggetto topico |
Antibody-drug conjugates
Drug delivery systems |
| ISBN |
1-280-58983-3
9786613619662 1-118-22889-8 1-118-22901-0 1-118-22884-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Antibody mediated drug delivery systems : a general review and applications / Navdeep Kaur, Karthikeyan Subramani, and Y.V. Pathak -- Immunoliposomes for cardiovascular targeting / Tatyana Levchenko, William Hartner, and Vladimir P. Torchilin -- Antibody mediated drug delivery systems for breast cancer therapeutics / Leonor Munoz Alcivar and Y.V. Pathak -- Development of immunonconjugates for in vivo delivery : cancer diagnosis, imaging, and therapy / Arut Selvan -- Mathematical models of anti-TNF therapies and their correlation with tuberculosis / Simeone Marino ... [et al.] -- Targeted nanoparticles in radiotherapy / Misty Muscarella and Y.V. Pathak -- Electrically-enhanced delivery of drugs and conjugates for cancer treatment / Arut Selvan, Luca Campana, and Raji Sundararajan -- Characterization of mAb variants and glycosylation / Ting Zheng ... [et al.] -- Antibody mediated drug delivery system for lymphatic targeting treatment / Fang Wu, Hong Ding, and Zhirong Zhang -- Methods for nanoparticle conjugation to monoclonal antibodies (mAbs) / Junling Li and Chin K. Ng -- Single use systems in animal cell-based bioproduction / William G. Whitford -- Immunoliposomes for specific drug delivery / Manuela Calin -- Gene therapy targeting kidney diseases : routes & vehicles / Yoshitaka Isaka, Yoshitsugu Takabatake, and Hiromi Rakugi -- Detection of antibodies to polyethylene glycol polymers using a double antigen bridging immunogenicity ELISA / Yijuan Liu ... [et al.] -- Antibodies in nanomedicine and microimaging methods / Rakesh Sharma -- Methods for polymeric nanoparticle conjugation to mAb / Uyen Minh Le, Hieu Tran, and Y.V. Pathak -- Plant-derived antibodies for academic, industrial, and therapeutic application / Slavko Komarnytsk and Nikolai Borisjuk -- Monoclonal antibodies as biopharmaceuticals / Girish J. Kotwal -- Pulmonary targeting of nanoparticles and monoclonal antibodies (mAb) / Weiyuan Chang -- Antibody mediated arthritis and new therapeutic avenues / Kutty Selva Nandakumar -- Immuno-nanoparticles for nuclear imaging and radiotherapy / Oren Giladi and Simon Benita -- Monoclonal antibodies in the treatment of asthma / Glenn J. Whelan. |
| Record Nr. | UNINA-9910141297903321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antibody-mediated drug delivery systems : concepts, technology, and applications / / edited by Yashwant Pathak, Simon Benita
| Antibody-mediated drug delivery systems : concepts, technology, and applications / / edited by Yashwant Pathak, Simon Benita |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (542 p.) |
| Disciplina | 615.37 |
| Altri autori (Persone) |
PathakYashwant
BenitaSimon <1947-> |
| Soggetto topico |
Antibody-drug conjugates
Drug delivery systems |
| ISBN |
9786613619662
9781280589836 1280589833 9781118228890 1118228898 9781118229019 1118229010 9781118228845 1118228847 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Antibody mediated drug delivery systems : a general review and applications / Navdeep Kaur, Karthikeyan Subramani, and Y.V. Pathak -- Immunoliposomes for cardiovascular targeting / Tatyana Levchenko, William Hartner, and Vladimir P. Torchilin -- Antibody mediated drug delivery systems for breast cancer therapeutics / Leonor Munoz Alcivar and Y.V. Pathak -- Development of immunonconjugates for in vivo delivery : cancer diagnosis, imaging, and therapy / Arut Selvan -- Mathematical models of anti-TNF therapies and their correlation with tuberculosis / Simeone Marino ... [et al.] -- Targeted nanoparticles in radiotherapy / Misty Muscarella and Y.V. Pathak -- Electrically-enhanced delivery of drugs and conjugates for cancer treatment / Arut Selvan, Luca Campana, and Raji Sundararajan -- Characterization of mAb variants and glycosylation / Ting Zheng ... [et al.] -- Antibody mediated drug delivery system for lymphatic targeting treatment / Fang Wu, Hong Ding, and Zhirong Zhang -- Methods for nanoparticle conjugation to monoclonal antibodies (mAbs) / Junling Li and Chin K. Ng -- Single use systems in animal cell-based bioproduction / William G. Whitford -- Immunoliposomes for specific drug delivery / Manuela Calin -- Gene therapy targeting kidney diseases : routes & vehicles / Yoshitaka Isaka, Yoshitsugu Takabatake, and Hiromi Rakugi -- Detection of antibodies to polyethylene glycol polymers using a double antigen bridging immunogenicity ELISA / Yijuan Liu ... [et al.] -- Antibodies in nanomedicine and microimaging methods / Rakesh Sharma -- Methods for polymeric nanoparticle conjugation to mAb / Uyen Minh Le, Hieu Tran, and Y.V. Pathak -- Plant-derived antibodies for academic, industrial, and therapeutic application / Slavko Komarnytsk and Nikolai Borisjuk -- Monoclonal antibodies as biopharmaceuticals / Girish J. Kotwal -- Pulmonary targeting of nanoparticles and monoclonal antibodies (mAb) / Weiyuan Chang -- Antibody mediated arthritis and new therapeutic avenues / Kutty Selva Nandakumar -- Immuno-nanoparticles for nuclear imaging and radiotherapy / Oren Giladi and Simon Benita -- Monoclonal antibodies in the treatment of asthma / Glenn J. Whelan. |
| Record Nr. | UNINA-9910809538703321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Basics and Clinical Applications of Drug Disposition in Special Populations
| Basics and Clinical Applications of Drug Disposition in Special Populations |
| Autore | Amponsah Seth Kwabena |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Newark : , : John Wiley & Sons, Incorporated, , 2025 |
| Descrizione fisica | 1 online resource (483 pages) |
| Disciplina | 615.7 |
| Altri autori (Persone) | PathakYashwant |
| Soggetto topico |
Pharmaceutical Preparations - metabolism
Pharmaceutical Preparations - administration & dosage Pharmacokinetics Drug Monitoring - methods Drug Therapy - methods |
| ISBN |
9781394251292
1394251297 9781394251308 1394251300 9781394251315 1394251319 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Dedication -- Contents -- About the Editors -- List of Contributors -- Foreword -- Preface -- Chapter 1 Pharmacokinetic Principles and Concepts: An Overview -- 1.1 Introduction -- 1.2 Pharmacokinetic Parameters -- 1.2.1 Absorption -- 1.2.2 Distribution -- 1.2.3 Metabolism -- 1.2.4 Excretion -- 1.3 Pharmacokinetic Models -- 1.4 Applications -- 1.5 Conclusion -- References -- Chapter 2 Model-Based Pharmacokinetic Approaches -- 2.1 Introduction -- 2.1.1 Importance of PK -- 2.1.2 Overview of Model-Based Approaches -- 2.2 Basics of Pharmacokinetics -- 2.2.1 Key Pharmacokinetic Parameters -- 2.2.1.1 Absorption -- 2.2.1.2 Key Parameter -- 2.2.1.3 Distribution -- 2.2.1.4 Key Parameter -- 2.2.1.5 Metabolism -- 2.2.1.6 Key Parameter -- 2.2.1.7 Excretion -- 2.2.1.8 Key Parameter -- 2.2.2 Differences Between Traditional and Model-Based Pharmacokinetic Approaches -- 2.3 Pharmacokinetic (PK) Models -- 2.3.1 Introduction -- 2.3.2 Compartment Modeling -- 2.3.2.1 One-CompartmentModel -- 2.3.2.2 Multi-CompartmentModel -- 2.3.2.3 Two-CompartmentModel -- 2.3.3 Population PK Model -- 2.3.4 Physiologically Based PK (PBPK) Model -- 2.4 Model Development and Validation -- 2.4.1 Data Requirements for Model Development -- 2.4.2 Data Requirements for Model Validation -- 2.4.3 Steps in Model Building (E.g., Model Selection and Parameter Estimation) -- 2.5 Applications of Model-Based Approaches -- 2.5.1 Dose Optimization -- 2.5.2 Predicting Drug Interactions -- 2.5.3 Drug Tailoring in Special Populations (E.g., Pediatrics, Geriatrics, and Renal Impairment) -- 2.5.4 Translational PK from Preclinical to Clinical Settings -- 2.6 Modeling in Special Populations -- 2.6.1 Challenges and Considerations -- 2.6.1.1 Challenges in PK Modeling -- 2.6.1.2 Considerations in PK Modeling -- 2.7 Software and Tools for PK Modeling -- 2.7.1 Gastroplus™.
2.7.2 Berkeley Madonna -- 2.7.3 MATLAB -- 2.7.4 PK-Sim® -- 2.7.5 Simcyp® -- 2.7.6 Auxiliary PBPK Modeling Software -- 2.7.6.1 Julia -- 2.7.6.2 NONMEM -- 2.7.6.3 Phoenix WinNonlin -- 2.7.6.4 GraphPad Prism -- 2.7.6.5 Minitab -- 2.7.6.6 PlotDigitizer -- 2.7.6.7 GNU MCSim -- 2.7.6.8 WebPlotDigitizer -- 2.8 Regulatory Perspectives of PK Modeling -- 2.9 Future Directions of PK Modeling -- 2.10 Conclusion -- Abbreviations -- References -- Chapter 3 Physiologically Based Pharmacokinetic Modeling -- 3.1 Introduction -- 3.2 Significance of PBPK Modeling -- 3.3 Principles for the Development of PBPK for Special Populations -- 3.4 Data Integration for Special Populations -- 3.4.1 Demographic Data -- 3.4.2 Physiological Consideration -- 3.4.3 Ontogeny -- 3.4.4 Age and Maturation Changes -- 3.4.5 Steady State Volume of Distribution (Vdss) -- 3.5 Applications of PBPK Modeling -- 3.5.1 Dose Optimization/Regimen/Selection -- 3.5.2 Dose Individualization/Precision Dosing -- 3.5.3 Biopharmaceutics -- 3.6 Regulatory Applications/Pre-Post Market Utilization -- 3.7 Case Studies -- 3.7.1 Simulation Application -- 3.7.2 Successful Applications -- 3.8 Lessons Learned -- 3.9 Conclusion -- References -- Chapter 4 Therapeutic Drug Monitoring in Special Populations -- 4.1 Introduction -- 4.2 Pediatrics -- 4.2.1 Importance of TDM in Pediatrics -- 4.2.2 Pharmacokinetic Differences in Pediatric Patients -- 4.2.3 Drug Absorption in the Pediatric Population -- 4.2.4 Drug Distribution in the Pediatric Population -- 4.2.5 Drug Metabolism and Elimination in the Pediatric Population -- 4.3 TDM Practices in Pediatrics -- 4.3.1 Vancomycin -- 4.3.2 Aminoglycosides -- 4.3.3 Ganciclovir/Valganciclovir -- 4.3.4 Antiepileptic Drugs (AEDs) -- 4.3.5 Enoxaparin -- 4.4 Conclusion -- 4.5 Pregnancy -- 4.5.1 Physiological Adaptations in Pregnancy. 4.5.2 Current State of Clinical Practice of TDM in Pregnancy -- 4.5.3 TDM in Pregnancy -- 4.5.3.1 Antiepileptics -- 4.5.3.2 Antidepressants -- 4.5.3.3 Antiretroviral Drugs -- 4.5.3.4 Immunomodulatory Drugs -- 4.5.4 Challenges in the Implementation of TDM in the Pregnant Population -- 4.6 The Elderly -- 4.6.1 Physiological Changes in the Elderly -- 4.6.2 Effect of Aging on Drug Pharmacokinetics -- 4.6.3 Application of TDM in the Elderly -- 4.6.3.1 Cardiac Glycosides -- 4.6.3.2 Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) -- 4.6.3.3 Anticoagulants -- 4.6.3.4 Benzodiazepines -- 4.7 Conclusion -- 4.8 Hepatic and Renal Impairments -- 4.8.1 Hepatic Impairment -- 4.8.2 TDM in Patients with Hepatic Impairment -- 4.8.2.1 Meropenem -- 4.8.2.2 Metoprolol -- 4.8.2.3 Midazolam -- 4.8.3 Renal Impairment -- 4.8.4 Prerenal Disease -- 4.8.5 Intrinsic Renal Vascular Disease -- 4.8.6 Intrinsic Glomerular Disease (Nephritic or Nephrotic) -- 4.8.7 TDM in Renal Impairment -- 4.8.7.1 Vancomycin -- 4.8.7.2 Metformin -- 4.9 Conclusion -- 4.10 Overall Conclusion and Future Direction -- Acknowledgment -- References -- Chapter 5 Optimization of Drug Dosing Regimen -- 5.1 Introduction -- 5.2 Dosing Regimen Optimization Approaches and Strategies -- 5.2.1 Models Used for Dosing Regimen Selection -- 5.2.1.1 Pharmacometric Models -- 5.2.1.2 PK Models -- 5.2.1.3 Empirical Dose-Response Models -- 5.2.1.4 Multiple Comparison Procedures Models (MCP-Mod) -- 5.2.1.5 Model Averaging -- 5.2.2 Role of Patient Characteristics in Dose Selection -- 5.2.2.1 Phenotype-GuidedDosing -- 5.2.2.2 Genotype-GuidedDrug Dosing -- 5.2.3 Therapeutic Drug Monitoring (TDM) -- 5.3 Dosing Regimen in Special Populations -- 5.3.1 Dosing Regimen in Cancer Patients -- 5.3.1.1 Metronomic Chemotherapy -- 5.3.2 Dosing Regimen for Patients on Antimicrobial Therapy -- 5.3.2.1 Antimicrobial Stewardship Strategy. 5.3.2.2 Mathematical Models for Optimizing Antimicrobial Therapy -- 5.3.2.3 Antimicrobial Dosing Strategies During CRRT -- 5.3.2.4 Methods for Enhancing Dosing of Antimicrobials via Nebulization -- 5.3.3 Dosing Regimen in Pediatric Patients -- 5.3.3.1 Physiological Differences Between Pediatric and Adult Patients -- 5.3.3.2 Application of MIDD in Pediatric Dose Selection -- 5.3.3.3 Scaling from Adults to Pediatric Patients -- 5.3.3.4 Scaling from Animals to Pediatric Patients -- 5.3.3.5 Integrating Mechanistic Models in Neonates and Infants -- 5.3.3.6 Dose Optimization in Neonates and Infants -- 5.4 Conclusion -- References -- Chapter 6 Artificial Intelligence in Drug Development -- 6.1 Introduction -- 6.2 Application of AI in Drug Design -- 6.2.1 Target Identification and Validation -- 6.2.2 Drug Candidate Design and Optimization -- 6.2.3 Virtual Screening and Molecular Docking -- 6.2.4 Synthesis Planning -- 6.2.5 Predicting Drug Toxicity and Pharmacokinetics -- 6.2.6 Personalized Medicine -- 6.3 AI Use in Drug Formulation -- 6.4 Drug Release Characterization Using AI -- 6.5 AI-Based Dose/Dosing Regimen -- 6.6 Dissolution Rate Predictions with AI -- 6.7 Clinical End-Point Evaluation with AI -- 6.8 AI in Prediction of Fate of Drugs Administered Via Mucosal, Transdermal, and Parenteral Routes -- 6.9 AI-Integrated Mechanistic Modeling Platform for Drug Delivery and Monitoring -- 6.10 AI-Based Tools for Metabolism and Clearance Prediction -- 6.11 Limitations of Existing Tools -- 6.12 Conclusions -- 6.13 Conflict of Interest -- Acknowledgments -- References -- Chapter 7 Drug Disposition in Neonates and Infants -- 7.1 Introduction -- 7.2 Drug Absorption in Neonates and Infants -- 7.3 Drug Distribution in Neonates and Infants -- 7.4 Hepatic Metabolism of Drugs in Neonates and Infants -- 7.4.1 Phase I Metabolism -- 7.4.2 Phase II Metabolism. 7.5 Drug Excretion in Neonates and Infants -- 7.6 Pharmacodynamics in Neonates and Infants -- 7.7 Age-Related Dosing Regimen in Neonates and Infants -- 7.8 Conclusion -- References -- Chapter 8 Drug Disposition in Adolescents -- 8.1 Introduction -- 8.2 Physiological Considerations in Adolescents -- 8.2.1 Organ Development: Liver and Kidney Maturation -- 8.2.2 Variations in Body Composition -- 8.2.3 Hormonal Changes -- 8.2.3.1 Males -- 8.2.3.2 Females -- 8.2.4 Other Physiological Changes -- 8.3 Medication Adherence Challenges in Adolescents -- 8.4 Psychological Development on Drug Disposition -- 8.5 Risk-Taking behaviors and Their Implications on Medication Use -- 8.6 Drug Use Among Adolescents -- 8.6.1 Acetaminophen Use in Adolescents -- 8.6.2 Antidepressant Use in Adolescents -- 8.6.3 Drugs for ADHD -- 8.7 Pharmacokinetic Variability in Adolescents Drug Examples -- 8.7.1 Acetaminophen -- 8.7.2 Theophylline -- 8.7.3 Antidepressants -- 8.7.4 Drugs for ADHD -- 8.8 Legal and Ethical Considerations -- 8.8.1 Consent and Confidentiality in Adolescent Healthcare -- 8.8.2 Involving Adolescents in Treatment Decisions -- 8.8.3 Regulatory Aspects of Adolescents Drug Prescribing -- 8.9 Conclusion -- References -- Chapter 9 Drug Disposition in Pregnancy -- 9.1 Introduction -- 9.2 Physiological Changes in Pregnancy -- 9.2.1 Changes in Absorption -- 9.2.2 Changes in Distribution and Free Medication -- 9.2.3 Changes in Cytochrome Metabolism -- 9.2.4 Changes in Renal Excretion -- 9.2.5 General Considerations in Drug Dosing with Pregnancy -- 9.3 Placental Drug Disposition -- 9.3.1 Placental Barrier Anatomy and Physiology -- 9.3.2 Placental Transport Mechanisms -- 9.3.3 Methods of Study for Placental Drug Transfer -- 9.4 Drug Classification in Pregnancy -- 9.5 Pharmacokinetic (PK) Modeling -- 9.6 Physiologically Based Pharmacokinetic (PBPK) Modeling. 9.7 Limitations in PK and PBPK Models. |
| Record Nr. | UNINA-9911019742603321 |
Amponsah Seth Kwabena
|
||
| Newark : , : John Wiley & Sons, Incorporated, , 2025 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug Delivery for the Retina and Posterior Segment Disease / / edited by Jayvadan K. Patel, Vijaykumar Sutariya, Jagat Rakesh Kanwar, Yashwant V. Pathak
| Drug Delivery for the Retina and Posterior Segment Disease / / edited by Jayvadan K. Patel, Vijaykumar Sutariya, Jagat Rakesh Kanwar, Yashwant V. Pathak |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (490 pages) : illustrations |
| Disciplina | 617.7061 |
| Soggetto topico |
Pharmaceutical technology
Ophthalmology Pharmaceutical Sciences/Technology |
| ISBN | 3-319-95807-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I- Introduction and basic concept of drug delivery for retina and posterior segment disease -- Anatomy and physiology of retina and posterior segment of the eye -- Pharmacotherapy of diabetic macular edema and retinopathy -- Drug delivery to posterior segment of eye: Conventional delivery strategies, their barriers and restrictions -- Penetration routes to retina and posterior segment -- Diabetic Retinopathy: Pathogenesis, Treatment, and Complications -- PART II-Nanotechnology based formulations for retina and posterior segment disease -- Liposomes for retina and posterior segment disease -- Nano/microparticles for retina and posterior segment disease -- Non-viral delivery systems for gene therapy for retina and posterior segment disease -- Oxidative stress in ocular disorders: Exploring the link to pesticide exposure and potential for using nanotechnology for antioxidant delivery -- Advances in the microbial infection in cornea and role of nanotechnology to cure ocular surface -- Nanomedicine based delivery to the posterior segment of eye: Brighter tomorrow -- Part III-Transscleral iontophoresis for retina and posterior segment disease -- Transscleral drug delivery to retina and posterior segment disease -- Colloidal carrier systems transscleral drug delivery -- Transscleral Iontophoretic Drug Delivery for Treating Retinal Diseases -- Part IV-Implant formulation for posterior eye segment -- Biodegradable polymeric implants for retina and posterior segment disease -- Nanomedicine based gene delivery for the retina and posterior segment diseases -- Part V-Prodrug strategies for retina and posterior segment disease -- Transporter targeted Pro-drug approach for retina and posterior segment disease -- Lipid Prodrug based delivery for retina and posterior segment disease -- Injectable Pro-drugs approach for retina and posterior segment disease -- Stereoisomeric dipeptide Pro-drug approach for retina and posterior segment disease -- Part VI-Other advances for retina and posterior segment diseases -- Receptor targeted Pro-drug approach for retina and posterior segment disease -- Intravitreal injection drug delivery for retina and posterior segment disease: Challenges and Future ahead -- Thermoresponsive gels drug delivery for retina and posterior segment disease -- Peptide synthesis and delivery for retina and posterior segment disease -- Corneal haze, refractive surgery and its implications on choroidal neovascularisation. . |
| Record Nr. | UNINA-9910298397603321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Emerging technologies for nanoparticle manufacturing / / Jayvadan K. Patel, Yashwant V. Pathak, editors
| Emerging technologies for nanoparticle manufacturing / / Jayvadan K. Patel, Yashwant V. Pathak, editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (604 pages) |
| Disciplina | 620.5 |
| Soggetto topico |
Nanomanufacturing
Nanopartícules |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-50703-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Preface -- Acknowledgments -- Contents -- Part I: Introduction and Biomedical Applications of Nanoparticles -- 1: Introduction to Nanomaterials and Nanotechnology -- 1 Introduction -- 2 Nanomaterials -- 3 Why Are Nanoscale Materials: So Special and Unique? -- 4 Classification of Nanoscale Materials -- 4.1 Classification of Nanomaterials Based on Their Origin -- 4.2 Classification of Nanomaterials Based on the Chemical Composition -- 4.3 Material-Based Classification -- 4.4 Classification of Nanomaterials Based on Their Dimensions -- 5 Properties: The Physics at the Nanoscale -- 5.1 Confinement Effect -- 5.2 Surface Effects -- 5.3 Mechanical Properties -- 5.4 Structural Properties -- 5.5 Thermal Properties -- 5.6 Optical Properties -- 5.7 Magnetic Properties -- 6 Nanomaterials Synthesis Strategies -- 6.1 Bottom-Up Procedures -- 6.2 Top-Down Procedures -- 7 Conclusion -- References -- 2: Biomedical Applications of Nanoparticles -- 1 Introduction -- 1.1 Applications of Nanoparticles in Biomedical -- 2 Conclusion -- References -- Part II: Polymeric Nanoparticles -- 3: Nanocrystallization and Nanoprecipitation Technologies -- 1 Introduction -- 2 Definition -- 3 Prominent Attributes -- 3.1 Surface Area Enlargement -- 3.2 Increase in Saturation Solubility -- 3.3 Crystalline or Amorphous Particle States -- 4 Production Technologies -- 5 Nanocrystallization and Nanoprecipitation Technologies -- 6 Media Milling -- 6.1 Mechanism Involved -- 6.2 Selection of Bead Size -- 6.3 Particle Surface Modification -- 7 Cryo-Milling -- 7.1 Definition -- 7.2 Ultra Cryo-Milling -- 8 Solvent-Antisolvent Precipitation -- 8.1 Fundamental Principle of Antisolvent Precipitation Techniques -- 8.2 Step-Up Antisolvent Precipitation Process -- 8.2.1 Mixing -- 8.2.2 Mixing Devices.
9 Role of Stabilizer in Antisolvent Precipitation Techniques -- 10 Future Perspectives -- References -- 4: Microfluidics Technology for Nanoparticles and Equipment -- 1 Introduction -- 2 Principle Foundation -- 3 Mixing -- 3.1 Active Micromixers -- 3.2 Passive Micromixers -- 4 Microfluidic Reactors: Features for the Manufacture of Nanoparticles -- 5 Design of the Reactor -- 6 Fabrication of Microfluidic Devices -- 7 Microfluidic Devices: Types -- 8 Formulation of Nano Drug Delivery System Using Microfluidics -- 8.1 Pure Drug Nanoparticles -- 8.1.1 Crystalline Drug Nanoparticles -- 8.2 Amorphous Drug Nanoparticles -- 8.3 API Loaded Nanoparticles Generated Using Microfluidic Technology -- 9 Microfluidic and Bulk Technologies: Comparison (Jahn et al. 2007) -- 10 Microfluidics: Nanoparticles Drug Delivery -- 10.1 Flow Focusing Method -- 10.2 Micro-vortices Method -- 10.3 Chaotic Flow Method -- 10.4 Droplets Method -- 10.5 Other Methods -- 11 Microfluidics: Nanoparticles Characterization -- 11.1 Characterization of Particle Size and Morphology -- 11.2 Charge Characterization -- 11.3 Characterization of Drug Loading and Drug Release -- 12 Microfluidics: Nanoparticle Evaluation -- 13 Production of Nanoparticles Using Microfluidic Devices -- 13.1 Lipid Nanoparticles (LNPs) -- 13.2 Polymeric Nanoparticles -- 13.3 Theranostic Nanoparticles -- 14 Microfluidic Tools for Nanoparticles Investigation -- 14.1 Organ-on-a-Chip -- 14.2 Blood Vessel-on-a-Chip -- 14.3 Blood Brain Barrier-on-a-Chip -- 14.4 Tumour-on-a-Chip -- 14.5 Lung-on-a-Chip -- 14.6 Liver-on-a-Chip -- 14.7 Kidney-on-a-Chip -- 14.8 Heart-on-a-Chip -- 15 Companies Working on Microfluidic Technology -- 16 Future Developments -- 17 Conclusion -- References -- 5: Production of Nanocomposites via Extrusion Techniques -- 1 Introduction. 2 Polymeric Nanocomposites by Extrusion Method -- 3 Metal Matrix Nanocomposites Prepared by Extrusion Method -- 4 Conclusion -- References -- 6: The Use of Supercritical Fluid Technologies for Nanoparticle Production -- 1 Introduction -- 2 Supercritical Fluid Technology -- 3 Supercritical Fluids -- 4 Supercritical Processes for Nanoparticles Manufacturing -- 4.1 Particles from Gas-Saturated Solutions (PGSS) -- 4.2 Rapid Expansion of Supercritical Solutions (RESS) -- 4.3 Gas Anti-solvent Processes (GAS) -- 4.4 Supercritical Anti-solvent Processes (SAS) -- 4.5 Aerosol Solvent Extraction System (ASES) -- 4.6 Supercritical Anti-solvent with Enhanced Mass Transfer (SAS-EM) -- 4.7 Solution-Enhanced Dispersion by Supercritical Fluids (SEDS) -- 4.8 Suspension-Enhanced Dispersion by Supercritical Fluids (SpEDS Process) -- 4.9 Supercritical Assisted Atomization (SAA) -- 5 Application of SCF for Production of Nanoparticles -- 6 Summary and Future Perspective -- References -- 7: Salting Out and Ionic Gelation Manufacturing Techniques for Nanoparticles -- 1 Introduction -- 2 Nanotechnology in Drug Delivery Systems -- 3 Polymeric Nanoparticles -- 4 Drug Releasing Mechanism of Nanoparticles -- 5 Development of Polymeric Nanoparticles -- 5.1 Polymerization -- 5.1.1 Emulsion-Polymerization Technique -- 5.1.2 Interfacial Polymerization Technique -- 5.2 Development of Polymeric Nanoparticles From Preformed Polymers -- 5.2.1 Emulsification and Solvent Evaporation Method -- 5.2.2 Solvent Displacement Technique -- 5.2.3 Interfacial Deposition Technique -- 5.2.4 Emulsification and Solvent Diffusion -- 5.2.5 Salting-Out Method -- Effect of Various Parameters on Salting-Out Technique -- Advantages of the Salting-Out Method -- Disadvantages of the Salting-Out Method -- Scale-Up of the Salting-Out Method. Effect of Process Parameters on the Quality of the Nanoformulation During the Scale-Up of Method -- The Theoretical Model for the Preparation of Nanoparticles by the Salting-Out Method -- Relation of the Rate of Stirring to the Nanoparticle Size -- Model for Drug Transport From the Salted-Out Scaffold -- Salting-Out Method and Transition of Polymer Properties -- Applications of the Salting-Out Method -- Preparation of PLGA- and PLA-Based Nanoformulations -- Preparation of Polymeric Nanoparticles for Gene Therapy by the Salting-Out Method -- Interactions Between Crosslinking Ions and Polymeric Chains -- Combination of the Salting-Out Method with Other Methods -- Emulsion Solvent Evaporation-Salting-Out Technique -- Emulsion-Based and Aqueous-Based Salting-Out Method -- 5.2.6 Supercritical Fluid Technology -- 5.2.7 Rapid Expansion of Supercritical Solution (RESS) -- 5.2.8 Rapid Expansion of Supercritical Solution into a Liquid Solvent -- 5.2.9 Electrospraying Technology -- 5.2.10 Ionic Gelation Method -- Chitosan-Based Nanoformulations -- Characterization of Chitosan -- Molecular Weight Determination -- Calculation of the Degree of Deacetylation -- Chitosan-Based Nanoparticles and Ionic Gelation Method -- 5.2.11 Microreactor Application in the Preparation of Chitosan Nanoparticles by Ionic Gelation Method -- 5.2.12 Theoretical Analysis of Nanoparticle Preparation by Ionic Gelation Method in a Microreactor -- 5.2.13 Hydrogels of Drug-Loaded Chitosan-Based Nanoparticle -- 5.2.14 Preparation of Alginate-Based Nanoparticles by Ionic Gelation Method -- Alginate Hydrogels -- Factors Influencing the Crosslinking Degree of Alginate-Based Hydrogels -- Evaluation of Hydrogels -- Preparation of Sodium Alginate Nanoparticles by Ionic Gelation Method -- Preparation Sodium Pectin-Based Nanoparticles by Ionic Gelation Method. Ionic Gelation Method for the Preparation of Nanogels -- Ionic Gelation Method for the Development of Nanoparticles Loaded Films -- 5.3 Effect of Process Parameters on the Quality of Nanoformulations -- 5.3.1 Polymer -- 5.3.2 Crosslinking Agent -- 5.3.3 Polymer and Drug Ratio -- 5.3.4 Sonication -- 5.4 Effect of Morphological and Physicochemical Properties on the Quality of Nanoformulation -- 5.4.1 Particle Size -- 5.4.2 Drug Loading and Entrapment Efficiency -- 5.4.3 Drug Release Kinetics -- 5.4.4 Degree of Swelling -- 5.4.5 Zeta Potential -- 5.4.6 Cellular Uptake of Nanoparticles -- 5.5 Modified Traditional Methods for the Development of Nanoparticles -- 5.5.1 Dialysis -- 5.5.2 Membrane Evaporation and Emulsion Technique -- 5.5.3 Premix Membrane Emulsification -- 5.5.4 Spray-Dry Method -- 5.5.5 Spray Solvent Displacement Combined with Dialysis -- 6 Conclusion -- References -- 8: Nanogel Synthesis by Irradiation of Aqueous Polymer Solutions -- 1 Introduction -- 2 Nanosized Particles in Medicine -- 3 Nanogels: Highlights and Applications -- 4 Synthesis Methods of Nanogels -- 4.1 Crosslinking/Polymerization of Monomer or Monomer Mixtures -- 4.2 Crosslinking of Preformed Polymers -- 5 Radiation-Induced Synthesis of Nanogels -- 5.1 Radiation Chemistry of Aqueous Systems -- 6 Conclusions and Future Prospects -- References -- 9: Cellulose Acetate-Based Nanofibers: Synthesis, Manufacturing, and Applications -- 1 Introduction -- 2 Derivatives of CA Polymer -- 3 Synthesis and Manufacturing of CA-Based Nanofibers -- 3.1 Electrospinning Process and Mechanism -- 3.2 Solvent Selection -- 3.2.1 Acetone-Based Solvent Systems -- (a) Using Water Acetone System -- (b) Acetone-DMF System -- (c) Using Acetone-DMAc Solvents -- 3.2.2 Other Solvent Systems -- 3.3 Deacetylation Study -- 4 Application of CA Nanofibers. 4.1 Antibacterial Application. |
| Record Nr. | UNINA-9910488720503321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genomics-Driven Healthcare : Trends in Disease Prevention and Treatment / / edited by Yashwant Pathak
| Genomics-Driven Healthcare : Trends in Disease Prevention and Treatment / / edited by Yashwant Pathak |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Adis, , 2018 |
| Descrizione fisica | 1 online resource (413 pages) |
| Disciplina | 615.7 |
| Soggetto topico |
Pharmaceutical technology
Health promotion Pharmaceutical Sciences/Technology Health Promotion and Disease Prevention |
| ISBN | 981-10-7506-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. Rethinking drug discovery and targeting after the genomic revolution -- Chapter 2. Living between sickness and health: Where is the human genome leading us? -- Chapter 3. Pharmacogenomics: Setting Newer Paradigms of Genetics in Therapy and Medicine -- Chapter 4. Bioinformatics and Pharmacogenomics: Tools to Understand and Accelerate Infectious Disease Control -- Chapter 5. Race and Ethnicity – Understanding Difference in the Genome Era -- Chapter 6. The Food Metabolome and Novel Dietary Biomarkers Associated with Diseases -- Chapter 7. Impact of genomics on drug discovery and clinical medicine -- Chapter 8. Genomics and drug transporters and application in drug discovery, delivery and development -- Chapter 9. Genomics and drug metabolizing enzymes its application in Drug delivery: Evaluating the influence of the microbiome -- Chapter 10. Essentials of Genomics in the Continuum of Translational Research -- Chapter 11. Charting a course for genomic medicine from base pair to bedside -- Chapter 12. Pharmacogenomics and pharmacoepigenomics: impact on therapeutic strategies -- Chapter 13. Clinical Pharmacogenomics and Personalized Medicine: New strategies to maximize drug efficacy and avoid adverse drug reaction -- Chapter 14. Epigenetic Patterns/Therapies associated with Genetic Disorders -- Chapter 15. Neurodegenerative disease conditions and genomic treatment for better health -- Chapter 16. Recent Trends in -Omics based methods and techniques for Lung Diseases prevention -- Chapter 17. Impact of Genomics on Personalization of Breast Cancer Care -- Chapter 18. Pharmacogenomics: a new approach for preventing severe cutaneous adverse drug reactions. |
| Record Nr. | UNINA-9910298422703321 |
| Singapore : , : Springer Singapore : , : Imprint : Adis, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of metallonutraceuticals / / edited by Yashwant Vishnupant Pathak, Jayant Nemchand Lokhande
| Handbook of metallonutraceuticals / / edited by Yashwant Vishnupant Pathak, Jayant Nemchand Lokhande |
| Pubbl/distr/stampa | Boca Raton : , : Taylor & Francis, , [2014] |
| Descrizione fisica | 1 online resource (346 p.) |
| Disciplina | 613.2/8 |
| Collana | Nutraceuticals |
| Soggetto topico |
Metals - Physiological effect
Metals - Therapeutic use |
| ISBN |
0-429-15163-2
1-4398-3699-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Front Cover; Contents; Series Preface; Foreword; Preface; Editors; Contributors; Chapter 1: Concept, Definition, and Need for Metallonutraceuticals; Chapter 2: Roles of Metals in Metabolism; Chapter 3: Ethnopharmacology and Ethnomedicine of Metals; Chapter 4: Characterization of Metallonutraceuticals; Chapter 5: Characterization, Bioavailability, and Drug Interactions of Metallonutraceuticals; Chapter 6: Therapeutic Applications of Nanometals; Chapter 7: Metallonanotherapeutics for Neurodegenerative Diseases; Chapter 8: Nanometals and Complexes in Cancer Diagnosis and Therapy
Chapter 9: Application of Metals in Traditional Chinese MedicineChapter 10: Metalloenzymes : Relevance in Biological Systems and Potential Applications; Chapter 11: Application of Nanosilver in Nutraceuticals; Chapter 12: Regulatory Pathways and Intellectual Property Rights for Metallonutraceuticals; Chapter 13: Gold Nanoparticles : A Promising Nanometallic Drug Delivery System with Many Therapeutic Applications; Back Cover |
| Record Nr. | UNINA-9910786833703321 |
| Boca Raton : , : Taylor & Francis, , [2014] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of Space Pharmaceuticals / / edited by Yashwant V. Pathak, Marlise Araújo dos Santos, Luis Zea
| Handbook of Space Pharmaceuticals / / edited by Yashwant V. Pathak, Marlise Araújo dos Santos, Luis Zea |
| Edizione | [1st ed. 2022.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 |
| Descrizione fisica | 1 online resource (1036 pages) |
| Disciplina |
616.980214
338.4761510919 |
| Soggetto topico |
Pharmaceutical chemistry
Aerospace engineering Astronautics Solar system Pharmaceutics Aerospace Technology and Astronautics Space Physics |
| ISBN | 3-030-05526-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Section I: Principles of Pharmaceuticals -- Section II: Effects of Spaceflight on Human Physiology and its Consequences on Drug Treatment -- Section III: Model Organisms for Pharmaceutical Research in Space -- Section IV: Simulated Microgravity for Pharmaceutical Research -- Section V: Translating Knowledge from Spaceflight Research to Earth Applications -- Section VI: Nutritional and Alternative Approaches to Treatment in Space. |
| Record Nr. | UNINA-9910559394703321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of Space Pharmaceuticals [[electronic resource] /] / edited by Yashwant Pathak, Marlise Araújo dos Santos, Luis Zea
| Handbook of Space Pharmaceuticals [[electronic resource] /] / edited by Yashwant Pathak, Marlise Araújo dos Santos, Luis Zea |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 |
| Disciplina | 615.19 |
| Soggetto topico |
Pharmaceutical technology
Aerospace engineering Astronautics Space sciences Pharmaceutical Sciences/Technology Aerospace Technology and Astronautics Space Sciences (including Extraterrestrial Physics, Space Exploration and Astronautics) |
| ISBN | 3-319-50909-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Section I: Principles of Pharmaceuticals -- Section II: Effects of Spaceflight on Human Physiology and its Consequences on Drug Treatment -- Section III: Model Organisms for Pharmaceutical Research in Space -- Section IV: Simulated Microgravity for Pharmaceutical Research -- Section V: Translating Knowledge from Spaceflight Research to Earth Applications -- Section VI: Nutritional and Alternative Approaches to Treatment in Space -- Section VII: Spaceflight Medical Incidents and Potential Pharmaceutical Solutions. |
| Record Nr. | UNINA-9910349448103321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
